AIM ImmunoTech (AIMAW) Stock Price, News & Analysis

Company Overview

AIM ImmunoTech, formerly known as Hemispherx Biopharma, is a clinical-stage biotechnology company dedicated to developing immune-based therapies for oncology, viral infections and other serious diseases. Its lead candidate, Ampligen (rintatolimod), is a proprietary Toll-like receptor 3 agonist being evaluated in combination regimens to boost anti-tumor responses in cancer patients and as a potential prophylactic or therapeutic agent against certain RNA viruses. In addition to Ampligen, the company is exploring next-generation immunomodulators designed to enhance the body’s natural defenses.

Founded in 1981 and headquartered in West Palm Beach, Florida, AIM ImmunoTech has pursued a global development strategy, conducting clinical trials in the United States and collaborating with research and manufacturing partners in Europe. The company has worked alongside government agencies and academic institutions to advance its pipeline, securing grants and contracts to support studies in chronic fatigue syndrome, immuno-oncology and emerging infectious diseases. These collaborations have helped AIM ImmunoTech refine its platform and expand its research footprint beyond domestic markets.

Led by a seasoned management team with expertise in drug development, regulatory affairs and commercial strategy, AIM ImmunoTech continues to advance its immunotherapeutic portfolio toward late-stage trials. The company’s strategic objectives include completing pivotal studies for Ampligen, exploring new indications for its immune-activating platform and forming potential licensing or co-development partnerships. By focusing on targeted modulation of the immune system, AIM ImmunoTech aims to address unmet medical needs in rapidly evolving therapeutic areas.

Key Stats

• Today's Range: $0.05 to $0.05
• 50-Day Range: $0.05 to $0.05
• 52-Week Range: $0.01 to $0.12
• Volume: N/A
• Average Volume: 32,382 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:AIMAW
• Previous Symbol: NASDAQ:AIMAW
• CIK: 1903464
• Web: www.aimimmunotech.com
• Phone: 646 722 2971
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A